Forecast

There is no analyst data available for this company.

News Go to news feed

ProMIS Neurosciences shares rise after positive phase‑1b interim data on PMN310

ProMIS Neurosciences stock rose 16.1% in premarket trading after the presentation of six‑month, blinded interim results from the phase‑1b PRECISE‑AD study of PMN310. Among 136 patients there were no ARIA‑E cases; the overall incidence of ARIA was 4.4% and was limited to mild, asymptomatic microbleeds. There were no treatment‑related serious adverse events or study‑related discontinuations. The data are viewed as strong evidence of safety, particularly in APOE4 carriers, and were accompanied by new analyst coverage (Chardan: buy, price target $20.00), which drove the share price from $11.72 to $13.61. » More on de.investing.com
ProMIS Neurosciences presents interim results of PMN310 phase 1b study

ProMIS Neurosciences is hosting a webinar to discuss the blinded six-month interim results of the PRECISE-AD Phase 1b study for PMN310. Discussions will focus on aggregated safety data and trends in selected biomarkers from patients with early-stage Alzheimer’s. PMN310 is a humanized monoclonal IgG1 antibody that targets toxic amyloid‑beta oligomers without binding to plaques or vascular deposits, potentially reducing the risk of amyloid-related imaging abnormalities. The randomized, double-blind study of 144 participants across three dose cohorts is fully recruited; PMN310 received FDA Fast-Track designation in July 2025. » More on de.investing.com
Private placement by ProMIS Neurosciences of up to $175 million secures funding for Alzheimer's study

ProMIS Neurosciences has entered into a securities purchase agreement for a PIPE financing of up to $175 million, led by Janus Henderson and the Ally Bridge Group, with participation from new and existing investors as well as management and the board. Approximately $75 million is expected initially, with an additional $100 million if warrants are exercised; common shares, warrants and pre-funded warrants will be sold. The proceeds are intended to finance the phase 1b Alzheimer’s study and development of a subcutaneous formulation of PMN310; ProMIS is targeting blinded top-line data in mid‑2026 and 12‑month data by the end of 2026. The transaction is expected to close on February 3, 2026, subject to customary conditions. » More on de.investing.com

Financials

In the last year, ProMIS Neurosciences had revenue of €0 and net profit of -€11.61M

(EUR)	2022	YoY
Revenue	0	100.00%
Gross profit	0	100.00%
Net profit	-11.61M	72.80%
EBITDA	-15.98M	161.58%

Fundamentals

Metric	Value
Market capitalization	€31.94M
Number of shares	8.58M
52-week high/low	€6.89 - €2.07
Dividends	No
Beta	1.19
P/E ratio	-0.83
PEG ratio	0.00
P/B ratio	2.59
P/S ratio	0.00

Company profile

ProMIS Neurosciences, Inc. erforscht und entwickelt Lösungen für die Präzisionsmedizin zur Behandlung von neurodegenerativen Erkrankungen, vor allem der Alzheimer-Krankheit (AD), der amyotrophen Lateralsklerose (ALS) und der Atrophie des multiplen Systems (MSA) in Kanada. Die firmeneigene Entdeckungsplattform umfasst die Algorithmen ProMIS und Collective Coordinates zur Vorhersage neuartiger Ziele, die als krankheitsspezifische Epitope auf der molekularen Oberfläche fehlgefalteter Proteine bekannt sind. Zu den führenden Produktkandidaten gehören PMN310, ein monoklonaler Antikörper (mAb) gegen toxische Oligomere bei Alzheimer, PMN267, ein Superoxid-Dismustase 1 und TAR-DNA-Bindungsprotein 43 bei ALS sowie Alpha-Synuclein bei der Parkinson-Krankheit und Lewy-Körper-Demenz, und PMN442, ein mAb gegen toxische a-syn-Oligomere und Seeding-Fibrillen bei MSA. Das Unternehmen war früher als Amorfix Life Sciences Ltd. bekannt und änderte im Juli 2015 seinen Namen in ProMIS Neurosciences, Inc. ProMIS Neurosciences, Inc. wurde im Jahr 2004 gegründet und hat seinen Hauptsitz in Toronto, Kanada.

Name	ProMIS Neurosciences
CEO	Gail M. Farfel
Headquarters	Toronto, on Canada
Website	promisneurosciences.com
Sector	Health Care
Industry	Pharmaceuticals
IPO	10/25/2007
Employees	6